Results 11 to 20 of about 800,324 (296)
European Journal of Cancer Supplements, 2013 The mean SPARC, FOXP3, CD8 or CD45RO expression levels in patients who did, or did not, receive adjuvant chemotherapy in stage II and III CRC. SPARC was significantly greater in patients with stage III CRC who did not require chemotherapy, whilst FOXP3 ...
David B. Abrams +132 more
core +4 more sources
Therapeutics and Clinical Risk Management, 2015 Katsuhiko Shimizu, Riki Okita, Shinsuke Saisho, Takuro Yukawa, Ai Maeda, Yuji Nojima, Masao Nakata Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Japan Background: Adjuvant chemotherapy after the complete resection of non ...
Shimizu K +6 more
doaj +1 more source
Chemotherapy adjuvant and chemotherapy-induced neutropenia
Taiwanese Journal of Obstetrics & Gynecology, 2022 Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
doaj +3 more sources
Thoracic Surgery Clinics, 2020 Five-year survival rates for patients with early-stage non-small cell lung cancer have room for improvement. Adjuvant chemotherapy results in a small but significant increase in overall survival at 5 years. Efforts to improve outcomes by intensifying adjuvant treatment, utilizing cancer-specific vaccines or tyrosine kinase inhibitors in unselected ...
Jessica A, Hellyer, Heather A, Wakelee
+5 more sources
Surgical Clinics of North America, 1986 At present, adjuvant chemotherapy exerts no significant impact on long-term survival and only occasionally provides brief palliation in head and neck cancer. The major contribution of chemotherapy has been in the preoperative period, when therapy for advanced squamous cell carcinoma may render some patients candidates for curative operations or ...
C K, Osborne, C A, Coltman
openaire +4 more sources
Adjuvant chemotherapy for medulloblastoma [PDF]
Cancer, 1985 The use of adjuvant chemotherapy for cerebellar medulloblastoma is controversial. Twenty-one children and adolescents were treated with adjuvant low-dose cyclophosphamide and vincristine following surgery and radiotherapy. With a mean observation period of 6 years, the disease-free survival is 81%.
S, McIntosh +7 more
openaire +2 more sources
Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer [PDF]
, 2011 Background: With increasing prevalence of diabetes mellitus and colon cancer, the number of patients suffering from both diseases is growing, and physicians are being faced with complicated treatment decisions.
Wouter M. W. Dercksen +15 more
core +1 more source
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]
, 2012 Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Viale, Giuseppe +16 more
core +5 more sources
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients : analysis of >4,500 patients from four German randomized breast cancer trials [PDF]
, 2008 Introduction: Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases.
Kümmel, Sherko +23 more
core +2 more sources
BMC Gastroenterology, 2020 Background Biliary tract cancers (BTC) have a poor prognosis even after curative resection because of frequent local and distant recurrences. Therefore, the importance of adjuvant therapy in BTC has been advocated to improve outcomes. However, the choice
Hyera Kim, Mi Hwa Heo, Jin Young Kim
doaj +1 more source